Amneal Pharmaceuticals (AMRX) Short-Term Debt issuances (2017 - 2025)
Historic Short-Term Debt issuances for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Q1 2025 value amounting to $218.0 million.
- Amneal Pharmaceuticals' Short-Term Debt issuances rose 35416.67% to $218.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $218.0 million, marking a year-over-year increase of 3885.35%. This contributed to the annual value of $48.0 million for FY2024, which is 7808.22% down from last year.
- Per Amneal Pharmaceuticals' latest filing, its Short-Term Debt issuances stood at $218.0 million for Q1 2025, which was up 35416.67% from $48.0 million recorded in Q1 2024.
- Amneal Pharmaceuticals' Short-Term Debt issuances' 5-year high stood at $218.0 million during Q1 2025, with a 5-year trough of $10.0 million in Q3 2023.
- For the 4-year period, Amneal Pharmaceuticals' Short-Term Debt issuances averaged around $81.4 million, with its median value being $80.0 million (2023).
- In the last 5 years, Amneal Pharmaceuticals' Short-Term Debt issuances crashed by 7647.06% in 2023 and then skyrocketed by 35416.67% in 2025.
- Amneal Pharmaceuticals' Short-Term Debt issuances (Quarter) stood at $85.0 million in 2022, then grew by 28.24% to $109.0 million in 2023, then plummeted by 55.96% to $48.0 million in 2024, then soared by 354.17% to $218.0 million in 2025.
- Its last three reported values are $218.0 million in Q1 2025, $48.0 million for Q1 2024, and $109.0 million during Q4 2023.